Metabolic dysfunction-associated steatotic liver disease: Evolution of the final terminology
European Journal of Internal Medicine · 2024-06 · 124 · 35-39
DOI: 10.1016/j.ejim.2024.04.013 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift European Journal of Internal Medicine, 2024-06. Verfasst von Piero Portincasa und 1 weiteren Autor:innen. Beteiligte Einrichtung: Clinica Medica "A. Murri", Department of Precision and Regenerative Medicine and Ionian Area (DiMePre-J), Medical School, University of Bari "Aldo Mo…. Hauptthemen laut MEDLINE: Terminology as Topic, Non-alcoholic Fatty Liver Disease. Die Arbeit wurde bisher 54-mal zitiert (Crossref) und nennt 47 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
The medical term nonalcoholic fatty liver disease (NAFLD) was coined in 1986 for a condition that has since become the most prevalent liver disorder worldwide. In the last 3 years, the global professional community launched 2 consecutive efforts to purge NAFLD from the medical dictionary and recommended new terms based on disease pathophysiology rather than distinction from similar conditions featuring liver steatosis. A consensus by renowned clinical scholars primarily residing in the Asian-Pacific region introduced metabolic dysfunction-associated fatty liver disease (MAFLD) as a new name to replace NAFLD in 2020. In 2023, a nomenclature and classification resulting in the term metabolic dysfunction-associated steatotic liver disease (MASLD) was developed by a large expert panel under the auspices of leading liver societies from Europe and Americas. These marked and rapid shifts in nomenclature have garnered the attention of many researchers and clinicians across the globe due to the multilevel impact of a frequent and potentially progressive chronic liver disease in both adult and pediatric populations. The proposed terminologies differ in several ways but they have more in common than differences. They both capture key features of liver disease associated with cardiometabolic risk factors and with significant impact on all-cause and liver-related mortality. The framework of MASLD has incorporated many innovative aspects of MAFLD and while several conceptual disparities remain a work in progress, global efforts should focus on new insights into disease pathogenesis, outcome trajectories, prevention, and treatment. Here, some of these challenges are discussed to facilitate this process.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Clinica Medica "A. Murri", Department of Precision and Regenerative Medicine and Ionian Area (DiMePre-J), Medical School, University of Bari "Aldo Moro", Piazza Giulio Cesare 11, Bari 70124, Italy. Electronic address: p…
- Division of Gastroenterology, Hepatology and Endoscopy, Department of Medicine, Harvard Medical School, Brigham and Women's Hospital, Boston, MA, USA; Section of Gastroenterology, Department of Medicine, VA Boston Healt…
Zitieren
APA
Portincasa, P., & Baffy, G. (2024). Metabolic dysfunction-associated steatotic liver disease: Evolution of the final terminology. European Journal of Internal Medicine, 124, 35-39. https://doi.org/10.1016/j.ejim.2024.04.013
Vancouver
Portincasa P, Baffy G. Metabolic dysfunction-associated steatotic liver disease: Evolution of the final terminology. European Journal of Internal Medicine. 2024;124:35-39. doi:10.1016/j.ejim.2024.04.013
BibTeX
@article{Portincasa2024,
author = {Portincasa, Piero and Baffy, Gyorgy},
title = {Metabolic dysfunction-associated steatotic liver disease: Evolution of the final terminology},
journal = {European Journal of Internal Medicine},
year = {2024},
volume = {124},
pages = {35--39},
doi = {10.1016/j.ejim.2024.04.013}
}
EUVIMED